BHV-8000

DRUG2 trials

Sponsors

Biohaven Therapeutics Ltd.

Conditions

Early Parkinson’s DiseaseParkinson Disease

Phase 2

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

RecruitingNCT06976268

Biohaven Therapeutics Ltd.Parkinson Disease

Start: 2025-05-28End: 2027-09-30Target: 550Updated: 2026-01-14

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease

Not yet recruitingCTIS2025-521113-13-00

Biohaven Therapeutics Ltd.Early Parkinson’s Disease

Target: 713Updated: 2025-12-22